HIGHBuilt-inPipeline
budoprutug and CLYM116 (entire clinical pipeline)
“10-K Item 1A: 'We do not have any product candidates that have gained regulatory approval, and we are substantially dependent on the success of budoprutug and CLYM116.'”
CLYM · Concentration risk · 10-K extracted
Climb Bio (CLYM) concentration risks
Updated
The most significant concentration Climb Bio discloses is budoprutug and CLYM116 (entire clinical pipeline), classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Climb Bio’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH2
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partyCounterparty
product candidate licensors (including Mabworks)
“10-K Item 1A: 'If we fail to meet payment or diligence obligations, licensors may terminate the agreements, resulting in the loss of rights to budoprutug, CLYM116 or any other product candidate we may license.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Climb Bio's risk is concentrated in its pipeline: the company has no approved products and is substantially dependent on the success of budoprutug and CLYM116, a high, structural concentration typical of a clinical-stage biotech with only two named assets. That concentration is made more acute by a licensing dependency — if Climb Bio fails to meet payment or diligence obligations to its product candidate licensors, including Mabworks, those licensors may terminate the agreements, resulting in loss of rights to budoprutug, CLYM116, or other candidates, also disclosed at a high level. The two exposures are tightly linked rather than independent: the entire value of the company rests on two unapproved candidates, and the rights to both ultimately depend on staying current with external licensors' terms. A single clinical setback or a licensing dispute could each independently threaten most of the company's asset base, since there is no broader marketed portfolio to absorb the loss. Both risks are well disclosed and inherent to the current stage of the business.
For the engine’s reasoning on CLYM’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| CLYM● | Climb Bio, Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.